ALSO SEVERAL Randy Travis FINANCIALINSTITUTIONS WHICH

ALSO, SEVERAL determines Randy Travis FINANCIALINSTITUTIONS WHICH 3 wooden crosses diagnoses ARE LENDERS UNDER HRP'S CREDIT FACILITY HAVE RECENTLYUNDERGONE CHANGES OF CONTROL OR EXPERIENCED FINANCIAL LOSSES. IN THESECIRCUMSTANCES, HRP DOES NOT KNOW IF ITS HISTORICAL LENDERS MAY BE WILLING ORABLE TO PROVIDE FUNDS WHICH HRP REQUESTS, IF THESE HISTORICAL LENDERS WILL BEINTERESTED TO MAKE LOANS AVAILABLE TO HRP WHEN EXISTING COMMITMENTS EXPIRE OR ONWHAT TERMS LOANS MAY BE AVAILABLE TO HRP IN THE FUTURE. * THIS PRESS RELEASE STATES THAT HRP`S REVOLVING UNSECURED CREDIT FACILITY DOESNOT MATURE UNTIL 2011, INCLUDING A ONE YEAR EXTENSION OPTION WHICH MAY BEEXERCISED BY HRP UPON PAYMENT OF A FEE. THE IMPLICATION OF THIS STATEMENT ISTHAT HRP WILL EXERCISE ITS OPTION TO EXTEND THE MATURITY OF THIS CREDIT FACILITYFROM 2010 TO 2011. IN FACT, HRP'S ABILITY TO EXERCISE ITS EXTENSION IS SUBJECTTO VARIOUS CONDITIONS BESIDES PAYMENT OF A FEE, AND ALTHOUGH HRP CURRENTLYBELIEVES IT IS IN COMPLIANCE WITH THESE OTHER CONDITIONS, THERE CAN BE NOASSURANCE THAT IT WILL REMAIN IN COMPLIANCE AT THE TIME THE EXTENSION OPTION MAYBE EXERCISED.

ALSO, HRP MAY DECIDE NOT TO EXERCISE THIS EXTENSION OPTION BUT TOSEEK A NEW, LONGER TERM CREDIT FACILITY BEFORE THE CURRENT 2010 MATURITY OF THISCREDIT FACILITY.FOR THESE REASONS, AMONG OTHERS, INVESTORS ARE CAUTIONED NOT TO PLACE UNDUERELIANCE UPON ANY FORWARD LOOKING STATEMENTS IN THIS PRESS RELEASE HRPT Properties TrustTimothy A Bonang, Director of Investor RelationsorKatherine L randy travis album . Johnston, Manager of Investor Relations617-796-8222 Business Wire 2009 randy trevis . LEXINGTON, Mass randytravis . & CAMBRIDGE, Mass.--(Business Wire)--Cubist Pharmaceuticals, Inc., (Nasdaq: CBST), a leading acute carebiopharmaceutical company, and Alnylam Pharmaceuticals, Inc three wooden crosses . (Nasdaq: ALNY), aleading RNAi therapeutics company, announced today that they have formed astrategic collaboration to develop and commercialize Alnylam`s ALN-RSV program.The RSV-specific RNAi therapeutic program includes ALN-RSV01, which is currentlyin Phase II clinical development for the treatment of respiratory syncytialvirus (RSV) infection in adult lung transplant patients, as well as severalother potent and specific second-generation RNAi-based RSV inhibitors inpre-clinical studies. The collaboration is structured as a 50/50 co-development and profit sharearrangement in North America, and a milestone- and royalty-bearing licensearrangement in the rest of the world outside of Asia, where ALN-RSV is partneredwith Kyowa Hakko Kirin Co., Ltd Alnylam will receive an upfront payment of $20million.

In addition, Alnylam is eligible to receive development and salesmilestone payments from Cubist that could total $82.5 million, for a total inupfront and potential milestone payments of $102.5 million, as well as doubledigit royalties on net sales outside of North America and Asia randy travis rise and shine . After achievingcertain development milestones, Alnylam could convert the North Americanco-development and profit share to a royalty-bearing license with developmentand sales milestones country music . Cubist will have sole rights for commercialization of theALN-RSV program worldwide outside of Asia, subject to the cost and profitsharing in North America randy traywick . "Cubist is pleased to be working with Alnylam and to be involved in thedevelopment and potential commercialization of a therapy for this significantinfectious disease," said Michael W Bonney, President and Chief ExecutiveOfficer of Cubist randy hatcher . "We expect that this collaboration will leverage thedevelopment expertise and commercial success we have achieved in the area ofinfectious disease. There is significant need for novel therapeutics toeffectively treat patients with RSV infection, a leading cause of pediatrichospitalization and a prevalent infection in certain adult populations. We areconvinced that developing a treatment for RSV infection is an importanttherapeutic and commercial opportunity, and, like Alnylam, are committed toaddressing this need." "We are excited to have formed this new alliance with Cubist - a like-mindedorganization that shares our commitment to bringing a novel RNAi therapeutic topatients infected with RSV.

We have tremendous respect for the Cubist team, andhave been impressed with the development and ongoing commercial success theyhave had with their lead anti-infective program, CUBICIN (daptomycin forinjection)," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam."Partnering this program brings additional critical mass to the advancement ofALN-RSV01 and/or second-generation RSV-specific RNAi therapeutics in our broaderprogram which we aim to advance through ongoing pre-clinical studies towardpotential clinical studies as early as 2010 . The partnership also providesAlnylam with yet additional financial flexibility to invest beyond RSV in themultiple product opportunities represented by our growing pipeline of novel RNAitherapeutics." In 2008, Alnylam conducted the GEMINI study in which ALN-RSV01 was evaluated ina double-blind, randomized, placebo-controlled Phase II clinical trial country music list . Datafrom this study showed that intranasally administered ALN-RSV01 demonstratedstatistically significant anti-viral efficacy with an approximately 40% relativereduction in RSV infection rate and a 95% increase in the number ofinfection-free subjects, as compared with placebo travis tritt . The RNAi therapeutic iscurrently being studied in a double-blind, randomized, placebo-controlled PhaseII clinical trial to assess the safety and tolerability of aerosolized ALN-RSV01in adult lung transplant patients naturally infected with RSV . As a secondaryobjective, this trial will evaluate the anti-viral activity of ALN-RSV01 inpatients with a naturally acquired RSV lower respiratory tract infection. Basedon these and other data, Cubist and Alnylam will aim to maximize the value ofthe entire RSV program for advancement in pediatric and adult RSV-infectedpatients. About Respiratory Syncytial Virus (RSV)RSV is a highly contagious virus that causes infections in both the upper andlower respiratory tract.